FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROBIN HOWARD W						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]								5. Relationship of Reportin (Check all applicable) X Director				ng Person(s) to Issuer	
	(First) (Middle) JEKTAR THERAPEUTICS JISSION BAY BOULEVARD SOUTH					3. Date of Earliest Transaction (Month/Day/Year) 11/15/2021									Officer (give title below) President			Other (below)	specify
(Street) SAN FRANCI					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applic Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				on	
(City)	(St	ate) (2	Zip)																
		Table	I - N	on-Deriva	tive	Secui	rities	Acc	quire	d, Dis	sposed of	, or B	enefi	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y					Execution Date,		·	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4					ties cially I Following	Fori (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Transa	saction(s) . 3 and 4)			(1130.14)
Common Stock ⁽¹⁾ 11/15/202:					1 ⁽²⁾				A		94,100	A	\$0	.00	0 518,223			D	
Common Stock 11/16/202				21				S		42,773 ⁽³⁾	D	\$13.	3.16 ⁽⁴⁾ 4'		75,450		D		
Common Stock																410			by spouse
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, th/Day/Year)		saction (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		vative irities ired r osed) r. 3, 4	Expir (Mon	te Exer ation D th/Day/	Year) Securiti Underly Derivati Security 3 and 4)		nt of ities lying ative ity (Instr	Der Sec (Ins	Price of rivative surity str. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
- 2. The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied.
- 3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 4. This transaction was executed in multiple trades at prices ranging from \$12.84 to \$13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.

Remarks:

11/17/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.